Largest Long-Term Study Confirms EDAP's AblathermŪ HIFU is Effective, Highly Reproducible Primary Treatment for Localized Prostate Cancer

Tuesday, May 17, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

-- 2,552 Patient, International, Multi-Center, 10-year Study Shows 83% of Patients Cancer Free --

Company Contact:

Blandine ConfortInvestor Relations / Legal Affairs+33 4 72 15 31 72[email protected]

Media/Investors:

Kim Muscara/Stephanie Carrington  646-536-7011/7017 [email protected] [email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store